Replies to post #97927 on Biotech Values

[DewDiligence]

Does BMY have more upside than PFE due to BMY having a greater participation than PFE in the economics of the Apixaban program or is it because Apixaban revenue will have more of an impact on BMY's bottom-line compared to PFE?

The latter.